155 related articles for article (PubMed ID: 33007508)
1. Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease.
Patel S; Siddiqui MB; Roman JH; Zhang E; Lee E; Shen S; Faridnia M; Mintini RJ; Boyett S; Idowu MO; Sanyal AJ; Luketic VA; Siddiqui MS
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2202-2204. PubMed ID: 33007508
[TBL] [Abstract][Full Text] [Related]
2. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.
Siddiqui MS; Fuchs M; Idowu MO; Luketic VA; Boyett S; Sargeant C; Stravitz RT; Puri P; Matherly S; Sterling RK; Contos M; Sanyal AJ
Clin Gastroenterol Hepatol; 2015 May; 13(5):1000-8.e3. PubMed ID: 25311381
[TBL] [Abstract][Full Text] [Related]
3. Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications.
Syed T; Siddiqui MS
Liver Transpl; 2021 Sep; 27(9):1326-1333. PubMed ID: 33837670
[TBL] [Abstract][Full Text] [Related]
4. LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.
Imajo K; Hyogo H; Yoneda M; Honda Y; Kessoku T; Tomeno W; Ogawa Y; Taguri M; Mawatari H; Nozaki Y; Fujita K; Kirikoshi H; Saito S; Sumida Y; Ono M; Wada K; Nakajima A; Eguchi Y
PLoS One; 2014; 9(12):e115403. PubMed ID: 25541989
[TBL] [Abstract][Full Text] [Related]
5. Dyslipidemia in nonalcoholic fatty liver disease.
Amor AJ; Perea V
Curr Opin Endocrinol Diabetes Obes; 2019 Apr; 26(2):103-108. PubMed ID: 30694825
[TBL] [Abstract][Full Text] [Related]
6. Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients.
Siddiqui MB; Arshad T; Patel S; Lee E; Albhaisi S; Sanyal AJ; Stravitz RT; Driscoll C; Sterling RK; Reichman T; Bhati C; Siddiqui MS
Hepatology; 2019 Jul; 70(1):98-107. PubMed ID: 30672598
[TBL] [Abstract][Full Text] [Related]
7. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy.
Sanches PL; de Piano A; Campos RM; Carnier J; de Mello MT; Elias N; Fonseca FA; Masquio DC; da Silva PL; Corgosinho FC; Tock L; Oyama LM; Tufik S; Dâmaso AR
J Clin Lipidol; 2014; 8(3):265-72. PubMed ID: 24793347
[TBL] [Abstract][Full Text] [Related]
8. Association between small dense LDL levels and hepatic fibrosis in patients with nonalcoholic fatty liver disease.
Young Kim S; Mun S; Yu JH; Jin YJ; Ju Suh Y; Cho SH; Lee JW
Medicine (Baltimore); 2022 Sep; 101(37):e30527. PubMed ID: 36123875
[TBL] [Abstract][Full Text] [Related]
9. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
10. De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients.
Idowu MO; Chhatrala R; Siddiqui MB; Driscoll C; Stravitz RT; Sanyal AJ; Bhati C; Sargeant C; Luketic VA; Sterling RK; Contos M; Matherly S; Puri P; Siddiqui MS
Liver Transpl; 2015 Nov; 21(11):1395-402. PubMed ID: 26228654
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.
Mikolasevic I; Milic S; Racki S; Zaputovic L; Stimac D; Radic M; Markic D; Orlic L
Perit Dial Int; 2016; 36(4):427-32. PubMed ID: 26475841
[TBL] [Abstract][Full Text] [Related]
12. Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: A focus on atherogenic dyslipidemia.
Amor AJ; Pinyol M; Solà E; Catalan M; Cofán M; Herreras Z; Amigó N; Gilabert R; Sala-Vila A; Ros E; Ortega E
J Clin Lipidol; 2017; 11(2):551-561.e7. PubMed ID: 28502513
[TBL] [Abstract][Full Text] [Related]
13. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
Santos RD; Valenti L; Romeo S
Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated lipid metabolism links NAFLD to cardiovascular disease.
Deprince A; Haas JT; Staels B
Mol Metab; 2020 Dec; 42():101092. PubMed ID: 33010471
[TBL] [Abstract][Full Text] [Related]
15. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
Connelly MA; Velez Rivera J; Guyton JR; Siddiqui MS; Sanyal AJ
Aliment Pharmacol Ther; 2020 Aug; 52(4):619-636. PubMed ID: 32638417
[TBL] [Abstract][Full Text] [Related]
16. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
17. Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study.
van den Berg EH; Wolters AAB; Dullaart RPF; Moshage H; Zurakowski D; de Meijer VE; Blokzijl H
Liver Int; 2019 Jul; 39(7):1343-1354. PubMed ID: 30968536
[TBL] [Abstract][Full Text] [Related]
18. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis.
Siddiqui MS; Sterling RK; Luketic VA; Puri P; Stravitz RT; Bouneva I; Boyett S; Fuchs M; Sargeant C; Warnick GR; Grami S; Sanyal AJ
Gastroenterology; 2013 Dec; 145(6):1271-9.e1-3. PubMed ID: 23973920
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risk: Is Imaging Helpful?
Doumas SA; Tripathi S; Kashikar A; Khuttan A; Kumar A; Singh H; Canakis JP; Ashish K; Dey D; Oppenheim I; Dey AK
Curr Probl Cardiol; 2024 Jan; 49(1 Pt B):102065. PubMed ID: 37652112
[TBL] [Abstract][Full Text] [Related]
20. NAFLD: An Emerging Causal Factor for Cardiovascular Disease.
Li M; Wang H; Zhang XJ; Cai J; Li H
Physiology (Bethesda); 2023 Nov; 38(6):0. PubMed ID: 37431986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
